StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) stock

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$4.00−0.06 (-1.48%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Taysha Gene Therapies profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Taysha Gene Therapies's profit margin for the twelve months ending Jun 30, 2026 was -2728.0%. For fiscal 2025 it was -1115.3%, against -1071.6% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1115.3%−43.6
FY2024Dec 31, 2024-1071.6%−349.6
FY2023Dec 31, 2023-722.1%+5913.2
FY2022Dec 31, 2022-6635.3%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-507.8%+919.8
Q2 FY2025Jun 30, 2025-1353.6%+528.4
Q1 FY2025Mar 31, 2025-935.2%−229.8
Q4 FY2024Dec 31, 2024-929.0%−2253.7
Q3 FY2024Sep 30, 2024-1427.5%+1039.6
Q2 FY2024Jun 30, 2024-1882.0%−855.0
Q1 FY2024Mar 31, 2024-705.4%−330.9
Q4 FY2023Dec 31, 20231324.7%–
Q3 FY2023Sep 30, 2023-2467.1%–
Q2 FY2023Jun 30, 2023-1027.1%–
Q1 FY2023Mar 31, 2023-374.5%–

More Taysha Gene Therapies figures

See a number that looks wrong?